Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
EpiEndo Pharma is a clinical-stage biopharmaceutical company with a unique therapeutic approach to chronic respiratory diseases like COPD and asthma. Their focus is on developing novel, orally available macrolide compounds that repair and enhance the integrity of the lung's epithelial barrier, rather than relying on traditional anti-inflammatory or bronchodilator mechanisms. Their lead candidate, EP395 (Barriolide™), aims to address the underlying epithelial dysfunction contributing to these conditions, potentially offering a first-in-class treatment. The company is advancing EP395 through clinical trials to establish its safety and efficacy in patients.
The Icelandic headquarters serves as the central hub for EpiEndo Pharma's research and development activities, clinical trial management, strategic planning, and corporate administration.
Likely housed within a modern science park or dedicated biotech facility offering advanced laboratory and office spaces, typical for innovative biopharmaceutical companies. Specific architectural details are not widely publicized.
The work culture at EpiEndo Pharma is expected to be highly collaborative, science-driven, and mission-focused, characterized by a dynamic start-up/biotech environment. Employees are likely dedicated to advancing novel treatments for significant unmet medical needs in respiratory health.
The Icelandic location highlights the country's supportive ecosystem for R&D and innovation in the life sciences, providing access to skilled talent and research collaborations.
While headquartered in Iceland, EpiEndo Pharma operates with a global perspective, particularly in its clinical development programs. They engage with clinical research organizations (CROs), trial sites, and regulatory authorities in multiple countries to advance their drug candidates. Their research collaborations and potential future commercialization efforts will also necessitate international engagement.
Kársnesbraut 94
Kópavogur
Capital Region (Höfuðborgarsvæðið)
Iceland
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, EpiEndo Pharmaceuticals' leadership includes:
EpiEndo Pharmaceuticals has been backed by several prominent investors over the years, including:
EpiEndo Pharma announced a key CFO transition in early 2024, appointing Páll Ragnar Jóhannesson to the role.
Discover the tools EpiEndo Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While EpiEndo Pharma does not publicly disclose its exact email format, common patterns for companies of its size and industry include [first_initial][last]@domain.com or [first].[last]@domain.com. These are estimations.
[first_initial][last]@epiendopharma.com or [first].[last]@epiendopharma.com
Format
mbech@epiendopharma.com (example based on CEO's name and common format)
Example
70%
Success rate
EpiEndo Pharma Press Release • February 21, 2024
EpiEndo Pharma announced positive topline results from its Phase 2a clinical trial of EP395 in COPD patients. The study met its primary endpoint of safety and tolerability and showed promising effects on biomarkers related to airway inflammation and epithelial integrity....more
EpiEndo Pharma Press Release • February 7, 2024
EpiEndo Pharma announced the appointment of Páll Ragnar Jóhannesson as its new Chief Financial Officer, succeeding Dr. Ivar S. Olafsson, who will continue to serve on the Board of Directors....more
EpiEndo Pharma Press Release • November 15, 2023
EpiEndo Pharma announced that Professor Wisia Wedzicha, a Principal Investigator for EpiEndo’s Phase 2a clinical study (EPICC), would present on 'Preventing COPD Exacerbations, an Unmet Need' at the 11th Annual COPD Conference....more
EpiEndo Pharma Press Release • May 23, 2023
EpiEndo Pharma announced the dosing of the first patient in its Phase 2a clinical study (EPICC™) evaluating EP395 in patients with Chronic Obstructive Pulmonary Disease (COPD)....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including EpiEndo Pharmaceuticals, are just a search away.